Stock AnalizJohnson & Johnson (JNJ) earnings for the quarter ended September 2026: EPS beats estimates
Johnson & Johnson reported results for the quarter ended September 2026 on October 13, 2026. Adjusted earnings per share came in at $2.59 against the analysts’ average forecast of $2.52, a beat of 2.7%.
Revenue for the quarter was $25.40 billion, up 5.9% from $23.99 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 5.7% on the first trading day after the report.
The last four quarters
Johnson & Johnson has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.59 | $2.52 | +2.7% | +6% | −5.7% |
| Jun 2026 | $2.90 | $2.85 | +1.6% | +7% | −1.5% |
| Mar 2026 | $2.70 | $2.68 | +0.9% | +10% | +0.3% |
| Dec 2025 | $2.46 | $2.46 | −0.1% | +9% | +0.1% |
What comes next
Analysts expect EPS of $2.92 for the next quarter on average and $11.12 for the fiscal year ending December 31, 2026.
The average analyst price target is $279.41, 2% below the current price of $285.75.
Valuation and score
Johnson & Johnson scores 2.6 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 43.4, and its intrinsic value under moderate assumptions is about 39% below the current market value. Full Johnson & Johnson analysis with 10 years of financials
Frequently asked questions
What was Johnson & Johnson’s EPS for the quarter ended September 2026?
$2.59 adjusted per share, against an analyst consensus of $2.52.
How much revenue did Johnson & Johnson report?
$25.40 billion, up 5.9% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.